GSK has begun the sale of some of its consumer health brands, hoping to raise around £1 billion before spinning off its consumer healthcare business, according to reports.

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Mehta said HUL's focus would continue to ensure uninterrupted supplies of COVID relevant portfolio and meeting the demand arising out of evolving consumer needs ...

The manufacturer, GSK, was going to stop manufacturing the brand-name medication in 2024 ... The FTC and others argued that ...

Mumbai: On 12 November 2024, Fireside Ventures, an early-stage venture fund focused on consumer brands, appointed Adarsh ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

We expect the company to benefit from a consumer shift in both developed and emerging markets toward higher-end beauty brands ... and vaccine space, GSK rejoins our list of best stocks to buy ...

Under his leadership, the North office was responsible for numerous global and Indian brands like, PepsiCo, Nestle, GSK, Hero ...

Haleon, the two-year-old CPG spinoff from GSK, is not only leading ... to Haleon’s pain relief brands, SeeMe also cited Kenvue’s Tylenol for prioritizing consumer wellness “through ...